These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34245852)

  • 1. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents.
    Wu F; Yao H; Li W; Zhang N; Fan Y; Chan ASC; Li X; An B
    Bioorg Med Chem Lett; 2021 Sep; 48():128253. PubMed ID: 34245852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
    Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
    Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.
    Cao M; Chen Y; Zhao T; Wei S; Guo M; Zhai X
    Bioorg Med Chem; 2020 Oct; 28(20):115715. PubMed ID: 33069079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects.
    Li T; Li C; Yang J; Guo M; Cao Z; Wang X; Jiang N; Zhai X
    Bioorg Med Chem; 2021 Oct; 47():116396. PubMed ID: 34534734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
    Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
    Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
    Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z
    Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation N
    Xing L; Jing T; Zhang J; Guo M; Miao X; Jiang F; Zhai X
    Bioorg Chem; 2018 Dec; 81():689-699. PubMed ID: 30268049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects.
    Li Z; Guo M; Cao M; Zhao T; Li M; Zhai X
    Bioorg Med Chem; 2021 May; 37():116108. PubMed ID: 33756437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a PROTAC targeting ALK with in vivo activity.
    Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
    Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors.
    Chen H; Li R; Ning X; Zhao X; Jin Y; Yin Y
    Eur J Med Chem; 2019 Sep; 178():141-153. PubMed ID: 31177074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
    Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
    Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
    Guo M; Zuo D; Zhao T; Li X; Cao J; Qiu Y; Wei S; Zhai X
    Eur J Med Chem; 2021 Mar; 214():113259. PubMed ID: 33581554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor.
    Achary R; Mathi GR; Lee DH; Yun CS; Lee CO; Kim HR; Park CH; Kim P; Hwang JY
    Bioorg Med Chem Lett; 2017 May; 27(10):2185-2191. PubMed ID: 28385505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
    Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
    Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42), a novel ALK inhibitor, induces apoptosis and protective autophagy in H2228 cells.
    Wang L; Xu X; Liu T; Wang J; Shen J; Guo M; Wu Y; Zhai X; Zuo D
    J Pharm Pharmacol; 2020 Oct; 72(10):1370-1382. PubMed ID: 32596809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.